Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
Showing 1-12 of 23 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-12 of 23 studies
-
Restore CFTR FunctionEnrolling
Study of Trikafta® in people with CF ages 12 years and older who have partial function CFTR mutations , protocol number Sorscher Partial Function Sub-StudyThis study will look at the effectiveness of Trikafta®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and evidence of partial CFTR function. Partial function is defined as a sweat chloride level < 80 mmol/L and/or pancreatic sufficiency (no pancreatic enzyme supplement therapy).
-
Age:
12 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
2 months
-
-
Restore CFTR FunctionEnrolling
Study of Trikafta® in people with CF ages 12 years and older who have an N1303K CFTR mutation , protocol number N1303K Sub-StudyThis study will look at the effectiveness of Trikafta, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and a least one of these mutations must be N1303K.
-
Age:
12 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
86 days
-
-
Restore CFTR FunctionClosed to Enrollment
Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part B) , protocol number VX20-445-111 PART BThis study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
2 Years to 5 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
9
-
Length of Participation:
32 weeks
-
-
Restore CFTR FunctionClosed to Enrollment
Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part A) , protocol number Vertex VX20-445-111 Part AThis study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
2 Years to 5 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
53 days
-
-
Restore CFTR FunctionCompleted with Results
Study of VX-445 Triple Combination in Teens and Adults With Cystic Fibrosis (CF) Who Have One Copy of F508del and One Copy of a Gating or Residual Function Mutation , protocol number Vertex VX18-445-104This study evaluated the safety and effectiveness of VX-445 (elexacaftor), tezacaftor, and ivacaftor in combination called TRIKAFTA®. This study was for people with CF 12 years and older with one copy of the F508del mutation and one copy of a gating or residual function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Restore CFTR FunctionCompleted with Results
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number Vertex VX18-445-106This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
9
-
Length of Participation:
32 weeks
-
-
Restore CFTR FunctionCompleted with Results
Study of VX-445 plus ivacaftor and tezacaftor in people with CF who have two copies of the F508del CFTR mutation , protocol number Vertex VX17-445-103This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with ivacaftor and tezacaftor. This triple combination is known as Trikafta™. This study was for people with CF ages 12 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor plus ivacaftor.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR FunctionCompleted with Results
Study of effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in people with CF who have one copy of the F508del CFTR mutation , protocol number Vertex VX17-445-102This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with tezacaftor and ivacaftor (ELX/TEZ/IVA). This triple combination drug is known as Trikafta™. This study was for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR FunctionCompleted with Results
Phase 3 study of VX-659 triple combination drug in people with CF ages 12 years and older who have two copies of the F508del mutation , protocol number VX17-659-103This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with two copies of the F508del CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR FunctionCompleted with Results
Phase 3 study of VX-659 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation , protocol number VX17-659-102This study evaluated the safety and effectiveness of the drug VX-659 in combination with tezacaftor and ivacaftor in people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR FunctionCompleted with Results
A study to evaluate tezacaftor/ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation , protocol number Vertex VX16-661-114This study evaluated the safety, effectiveness, and tolerability of the drug tezacaftor/ivacaftor (Symdeko®). This study was for people with CF ages 12 and older with two copies of the F508del CFTR mutation who had been taken off lumacaftor/ivacaftor (Orkambi®) due to respiratory side effects.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
25 to 90%
-
Number of Visits:
5
-
Length of Participation:
84 days
-
-
Restore CFTR FunctionCompleted with Results
Phase 2 study of VX-659 combination drug in adults with cystic fibrosis , protocol number Vertex VX16-659-101This study evaluated the safety, tolerability and effectiveness of the drug VX-659 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
8 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More